Status:

TERMINATED

Mitochondrial Function in Transthyretin Amyloidosis

Lead Sponsor:

University Hospital Center of Martinique

Conditions:

Cardiac Amyloidosis

Eligibility:

All Genders

18+ years

Brief Summary

Hereditary (familial) amyloidosis arising from the misfolding of a mutated or variant transthyretin, is the most frequent form of amyloid cardiomyopathy in the Caribbean basin. Affected organs invaria...

Detailed Description

Systemic amyloidosis are a family of diseases induced by misfolded and/or misassembled proteins. Extracellular deposits of these proteins disrupt vital organ function. Two types of amyloid commonly in...

Eligibility Criteria

Inclusion

  • Have a parietal thickness measuring more than 15 mm on the echocardiography or have structural and echogenicity abnormalities characteristic of cardiac amyloidosis,
  • Live in Martinique,
  • Accept the use of the residues coming from biopsies of the subcutaneous abdominal adipose tissue performed during the medical care.

Exclusion

  • Be under 18 years old,
  • Have a contraindication to subcutaneous biopsy,
  • Be allergic to local anesthetics,
  • Pregnant or nursing woman,
  • Have a cardiovascular disease suggesting a secondary cardiac disease, such as documented severe hypertension, valvular stenosis, or a known familial cardiomyopathy,
  • Be major under guardianship / curatorship or deprived of liberty,
  • Not be able to answer to a simple administrative questionnaire or to give freely its non-opposition.

Key Trial Info

Start Date :

July 17 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 29 2019

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT03328338

Start Date

July 17 2018

End Date

December 29 2019

Last Update

August 28 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHU de Martinique

Fort-de-France, Martinique, 97261